Respironics Introduces REMstar(R) Plus

The Leading Sleep Technology Gets Better



Apr 16, 2001, 01:00 ET from Respironics, Inc.

    PITTSBURGH, April 16 /PRNewswire/ -- RESPIRONICS, INC. (Nasdaq:   RESP)
 announced today the launch of REMstar Plus -- the first in a new line of CPAP
 systems used for the treatment of sleep apnea.  "I am confident that our new
 REMstar platform will further expand the Company's lead in the expanding sleep
 disorders breathing market," stated James W. Liken, president and chief
 executive officer.
     The first in a series, the REMstar Plus focuses on two highly important
 issues -- patient comfort and compliance.  The product's most noteworthy
 change is the unit's integrated approach to humidification; additionally, the
 REMstar's vast new array of features and its contemporary sleek new look
 further distinguish this product as a truly unique offering for the sleep
 market.  "Our first objective was the comfort of the patient," explained
 Mr. Liken.  "It is a fact that when a sleep patient using CPAP experiences
 discomfort from dry nasal passages, that patient is less likely to comply with
 their prescribed treatment schedule.  Respironics addressed this problem by
 applying its technical expertise to the issues surrounding humidification;
 with proper humidification, compliance naturally follows," Mr. Liken
 continued.
     The new platform provides greater flexibility.  It gives the healthcare
 provider the option to transition patients from no humidification, to room
 temperature humidification, to heated humidification with one device.  While
 doing so, it also gives providers an opportunity to efficiently manage their
 product inventory and eliminates the need to purchase CPAP equipment from any
 other vendor.  "We understand the importance of patient compliance and
 outcomes to our customers and their businesses.  We also understand the
 importance of keeping inventories low.  This technology, combined with our
 Power Programs(TM), provides our customers with 'the tools' that they need to
 grow their businesses," said Mr. Liken.
     The introduction of the REMstar platform presents an added benefit to
 Respironics by allowing the Company to streamline its model offering and
 simplify market segmentation.  For further information on REMstar Plus visit
 our website at http://www.respironicsremstar.com .
 
     Respironics, a recognized resource in the medical device market, provides
 innovative products and unique programs to health care providers while helping
 them to grow and manage their business efficiently.  The company's focus is on
 home care, hospital and international markets providing programs that manage
 sleep disordered breathing, chronic obstructive pulmonary disease, asthma,
 infant care and restrictive lung disorders.  Globally positioned, the company
 employs nearly 1,900 individuals worldwide and has manufacturing facilities in
 several domestic and international locations.  Further information on
 Respironics can be found on its web site: www.respironics.com .
 
     This press release contains forward-looking statements, including
 statements relating to developments in the healthcare industry, third-party
 reimbursement policies and practices, future sales and acceptance of the
 company's products and Power Programs(TM), new product development and
 regulatory requirements, which are subject to change.  Actual results may
 differ materially from those described in any forward-looking statements.
 Additional information on potential factors that could affect the company's
 financial results are included in the reports filed with the SEC, including
 the reports on Form 10-K, 10-Q and 8-K.
 
 

SOURCE Respironics, Inc.
    PITTSBURGH, April 16 /PRNewswire/ -- RESPIRONICS, INC. (Nasdaq:   RESP)
 announced today the launch of REMstar Plus -- the first in a new line of CPAP
 systems used for the treatment of sleep apnea.  "I am confident that our new
 REMstar platform will further expand the Company's lead in the expanding sleep
 disorders breathing market," stated James W. Liken, president and chief
 executive officer.
     The first in a series, the REMstar Plus focuses on two highly important
 issues -- patient comfort and compliance.  The product's most noteworthy
 change is the unit's integrated approach to humidification; additionally, the
 REMstar's vast new array of features and its contemporary sleek new look
 further distinguish this product as a truly unique offering for the sleep
 market.  "Our first objective was the comfort of the patient," explained
 Mr. Liken.  "It is a fact that when a sleep patient using CPAP experiences
 discomfort from dry nasal passages, that patient is less likely to comply with
 their prescribed treatment schedule.  Respironics addressed this problem by
 applying its technical expertise to the issues surrounding humidification;
 with proper humidification, compliance naturally follows," Mr. Liken
 continued.
     The new platform provides greater flexibility.  It gives the healthcare
 provider the option to transition patients from no humidification, to room
 temperature humidification, to heated humidification with one device.  While
 doing so, it also gives providers an opportunity to efficiently manage their
 product inventory and eliminates the need to purchase CPAP equipment from any
 other vendor.  "We understand the importance of patient compliance and
 outcomes to our customers and their businesses.  We also understand the
 importance of keeping inventories low.  This technology, combined with our
 Power Programs(TM), provides our customers with 'the tools' that they need to
 grow their businesses," said Mr. Liken.
     The introduction of the REMstar platform presents an added benefit to
 Respironics by allowing the Company to streamline its model offering and
 simplify market segmentation.  For further information on REMstar Plus visit
 our website at http://www.respironicsremstar.com .
 
     Respironics, a recognized resource in the medical device market, provides
 innovative products and unique programs to health care providers while helping
 them to grow and manage their business efficiently.  The company's focus is on
 home care, hospital and international markets providing programs that manage
 sleep disordered breathing, chronic obstructive pulmonary disease, asthma,
 infant care and restrictive lung disorders.  Globally positioned, the company
 employs nearly 1,900 individuals worldwide and has manufacturing facilities in
 several domestic and international locations.  Further information on
 Respironics can be found on its web site: www.respironics.com .
 
     This press release contains forward-looking statements, including
 statements relating to developments in the healthcare industry, third-party
 reimbursement policies and practices, future sales and acceptance of the
 company's products and Power Programs(TM), new product development and
 regulatory requirements, which are subject to change.  Actual results may
 differ materially from those described in any forward-looking statements.
 Additional information on potential factors that could affect the company's
 financial results are included in the reports filed with the SEC, including
 the reports on Form 10-K, 10-Q and 8-K.
 
 SOURCE  Respironics, Inc.